Ascendis Pharma mit starkem Studiendaten – Goldman Sachs bleibt sensible Von Investing.com

Investing.com – US investment bank Goldman Sachs (NYSE:) has paid down the share price of Ascendis Pharma (NASDAQ:) from $180 to $200 and put the shares at “Buy” prices. Analyst Paul Choi comments on the positive remarks about the phase 3 “ApproaCH” study of TransCon CNP for achondroplasia.

The study has begun when the secondary endpoint is reached, and the drug is generally very attractive, whether it is a breakdown or a hypothetical loan. Laut Choi has died of the law of TransCon CNP in the context of BioMarin’s Voxogo (Vosoritide) and BridgeBio’s Infigratinib. In addition, it is so that the dosage is such that a simple injection in the display of the label of the competitor’s preparation is possible.

Although it is so, the further involvement of TransCon CNP was involved, and there were now more detailed studies on regulatory updates. Ascendis plane, in the first Quarter 2025 a Zulassungsantrag (NDA) in the US and in the third Quarter 2025 a deferred approval (MAA) in the EU requirement.

The Kursziel could raise the expected forecast to $200.

In own pocket: Do you want to know what investors’ portfolio results are? InvestingPro gives you access to the strategies and portfolios of top investors. There are always more than 100 actions performed, which are based on AI analyses. Curious? Click here for more information.